Kunkel Lori Anne

October 11, 2026

Enliven's ENABLE-2 Trial Design Sparks New Questions. Enliven Therapeutics has clarified the design of its ENABLE-2 Phase 3 trial for relcobatinib in chronic myeloid leukemia, following questions raised by the trial’s structure. The company also confirmed FDA alignment on the study, while a separate patent dispute involving Halozyme and Merck has kept the leukemia treatment landscape in focus. These developments highlight the regulatory and strategic challenges Enliven faces as it moves toward clinical milestones.

October 15, 2026

JP Morgan Upgrades ORIC, Raises Target to $26. JP Morgan has upgraded ORIC to Overweight and lifted its price target to $26, reflecting confidence in the company’s pipeline. A recent Yahoo article questions whether ORIC’s off‑balance‑sheet funding for project ORIC‑259 changes its R&D risk profile. These developments add new context to the stock’s current technical position near its 200‑day SMA and a support level of $8.69.

October 12, 2026

Nurix Advances Bexobrutideg Studies and Secures $10M Gilead Extension. Nurix has enrolled its first patient in a Phase 1b/2 study of Bexobrutideg for chronic lymphocytic leukemia, and a second enrollment began for a Bexobrutideg plus Venetoclax combination under a Roche partnership. The company also received a second research term extension for its oncology program with Gilead Sciences and secured $10 million from Gilead as part of the extended drug‑discovery collaboration. These developments show ongoing progress in Nurix’s pipeline and continued partnership support.